Leqembi finally "takes off"? Biogen (BIIB.US) Q1 performance beats pessimistic expectations, with sales of Alzheimer's drug skyrocketing by 74%.

According to the financial news app Zhitong Finance, pharmaceutical company Biogen (BIIB.US) released its first-quarter financial report on Wednesday, showing that Q1 revenue increased by 2% to $2.5 billion; adjusted earnings per share were $3.57, an 18% year-on-year increase, exceeding market expectations. The sales growth of the Alzheimer's drug Leqembi and cost-cutting measures partially offset the pressure faced by the company's multiple sclerosis (MS) business segment.